AAPL 245.215 0.1409% MSFT 417.3999 0.6341% NVDA 139.51 0.2011% GOOGL 184.6399 -0.3401% GOOG 186.525 -0.3233% AMZN 222.24 -1.9371% META 696.265 -1.0664% AVGO 225.7 -1.3247% LLY 872.6701 0.6482% TSLA 352.99 -2.0995% TSM 199.8 -0.5723% V 349.7601 -1.5398% JPM 266.93 -4.4118% UNH 502.69 -1.6339% NVO 83.71 0.3717% WMT 97.34 -6.4038% LVMUY 146.15 1.7403% XOM 111.96 1.505% LVMHF 723.3 0.1254% MA 560.005 -1.4943%
AAPL 245.215 0.1409% MSFT 417.3999 0.6341% NVDA 139.51 0.2011% GOOGL 184.6399 -0.3401% GOOG 186.525 -0.3233% AMZN 222.24 -1.9371% META 696.265 -1.0664% AVGO 225.7 -1.3247% LLY 872.6701 0.6482% TSLA 352.99 -2.0995% TSM 199.8 -0.5723% V 349.7601 -1.5398% JPM 266.93 -4.4118% UNH 502.69 -1.6339% NVO 83.71 0.3717% WMT 97.34 -6.4038% LVMUY 146.15 1.7403% XOM 111.96 1.505% LVMHF 723.3 0.1254% MA 560.005 -1.4943%

Kalkine Bearish Chart Report

Bearish Indication on Two NASDAQ- Listed Stocks– CUE, ABP

Jan 29, 2025

CUE:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)
ABP:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Company Overview:

Cue Biopharma, Inc. (NASDAQ: CUE) is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. This Report covers the Action, Technical Indicators Analysis along with the Support Levels, Resistance Level, and Trend Indication on this one stock. Noted below is the illustrative bearish score based on technical indicators for the stock:

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.